By a GenomeWeb staff reporter NEW YORK (GenomeWeb News) – Beckman Coulter's president has issued a letter to employees informing them that 8 percent of the company's workforce will be laid off as part of the company's restructuring.
By Bernadette TonerThis article was originally published Aug. 19.
The companies have reached a settlement in an intellectual property lawsuit related to technology for isolating and purifying nucleic acids.
During a conference call, Danaher's CEO said that although issues surrounding broad quality systems at Beckman Coulter, as well issues with FDA are improving, there "is plenty of work ahead of us."
Thomas Schinecker, Kip Miller, Kevin McKernan
Beckman Coulter Genomics Target Capture Sequencing Service; Illumina TruSeq Custom Enrichment; Ion Torrent Barcoding, Library Quantitation, Ion Sphere Control Kits
Beckman Coulter announced changes to its board, Steven Salzberg moves to Johns Hopkins, Complete Genomics names a new senior vice president and chief commercial officer, and more.
The tender offer period finished with around 92 percent of Beckman Coulter shareholders tendering their shares.
Danaher commenced a subsequent offering period set to expire on June 29, after which it expects to complete its purchase of Beckman Coulter.
The European Commission approved the deal, clearing the way for Danaher to complete the $6.8 billion purchase by the end of the month.
US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.
Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.
Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.
In Science this week: almond reference genome, and more.